Juvenescence Us Corp. - Net Worth and Insider Trading

Juvenescence Us Corp. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Juvenescence Us Corp. owns 1 companies in total, including AgeX Therapeutics Inc (AGE) .

Click here to see the complete history of Juvenescence Us Corp.’s form 4 insider trades.

Insider Ownership Summary of Juvenescence Us Corp.

Ticker Comapny Transaction Date Type of Owner
AGE AgeX Therapeutics Inc 2023-03-14 director & 10 percent owner

Juvenescence Us Corp. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Juvenescence Us Corp. Ownership Network

Ownership Network List of Juvenescence Us Corp.

No Data

Ownership Network Relation of Juvenescence Us Corp.


Juvenescence Us Corp. Owned Company Details

What does AgeX Therapeutics Inc do?

Who are the key executives at AgeX Therapeutics Inc?

Juvenescence Us Corp. is the director & 10 percent owner of AgeX Therapeutics Inc. Other key executives at AgeX Therapeutics Inc include Chief Financial Officer Park Andrea Eun Jae , director & Chief Executive Officer Michael D West , and Chief Financial Officer Russell Skibsted .

AgeX Therapeutics Inc (AGE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AgeX Therapeutics Inc (AGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AgeX Therapeutics Inc (AGE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AgeX Therapeutics Inc (AGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

AgeX Therapeutics Inc Insider Transactions

No Available Data

Juvenescence Us Corp. Mailing Address

Above is the net worth, insider trading, and ownership report for Juvenescence Us Corp.. You might contact Juvenescence Us Corp. via mailing address: 303a College Road East, Princeton Nj 08540.

Discussions on Juvenescence Us Corp.

No discussions yet.